1. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300:51–9. [PubMed] 2. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med. 2007;146:87–95. [PubMed] 3. Gazzard BG. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563–608. [PubMed] 5. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22:1951–60. [PMC free article] [PubMed] 6. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9:65–71. [PubMed] 7. Hammer SM, Eron JJ, Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society—USA panel. JAMA. 2008;300:555–70. [PubMed] 8. Gallant JE. Should antiretroviral therapy be started earlier? Curr HIV/AIDS Rep. 2007;4:53–9. [PubMed] 10. Almond LM, Hoggard PG, Edirisinghe D, et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother. 2005;56:738–44. [PubMed] 11. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287–300. [PubMed] 12. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005;192:1931–42. [PubMed] 13. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005;40:1358–61. [PubMed] 14. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41:1648–53. [PubMed] 15. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1–5. [PubMed] 16. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391–400. [PubMed] 17. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007;45:1230–7. [PubMed] 18. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006;61:148–54. [PubMed] 19. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007;81:557–66. [PubMed] 20. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;16:191–8. [PubMed] 21. Molina JM, Peytavin G, Perusat S, et al. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial) HIV Med. 2004;5:99–104. [PubMed] 22. Molina JM, Journot V, Furco A, et al. Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial) Antivir Ther. 2007;12:417–22. [PubMed]
23. Nelson M, Staszewski S, Morales-Ramirez JO, et al. Successful virologic suppression with efavirenz in HIV-infected patients with low baseline CD4 cell counts: post hoc results from study 006. Abstracts of the Tenth European Congress of Clinical Microbiology and Infectious Diseases; 2000; Stockholm, Sweden. Abstract 3-349.
24. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther. 2003;8:339–46. [PubMed] 25. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–106. [PubMed]
26. Sierra-Madero J, Villasis-Keever A, Mendez P, et al. A prospective, randomized, open label trial of efavirenz vs lopinavir/ritonavir based HAART, among HIV infected naive individuals pesenting for care with CD4+ cell counts <200 cell/mm3 in Mexico. Abstracts of the Seventeenth International AIDS Conference; 2008; Mexico City, Mexico. Abstract TUAB0104.
27. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253–63. [PubMed] 28. van den Berg-Wolf M, Hullsiek KH, Peng G, et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials. 2008;9:324–36. [PubMed] 29. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850–61. [PubMed] 30. DeJesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39:411–8. [PubMed] 31. Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38:417–25. [PubMed] 32. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39:1038–46. [PubMed] 33. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296:769–81. [PubMed] 34. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201. [PubMed] 35. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180–9. [PubMed] 36. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–60. [PubMed] 37. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47:74–8. [PubMed] 38. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011–9. [PubMed] 39. Yeni P, Cooper DA, Aboulker JP, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet. 2006;368:287–98. [PubMed] 40. Friedl AC, Ledergerber B, Flepp M, et al. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS. 2001;15:1793–800. [PubMed] 41. Pulido F, Arribas JR, Miró JM, et al. Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study) J Acquir Immune Defic Syndr. 2004;35:343–50. [PubMed] 42. Torti C, Maggiolo F, Patroni A, et al. Exploratory analysis for the evaluation of lopinavir/ritonavir- versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER cohort. J Antimicrob Chemother. 2005;56:190–5. [PubMed]
43. Pulido F, Arribas J, Moreno S. Similar virologic and immunologic response to efavirenz or lopinavir/ritonavir-based HAART in a large cohort of antiretroviral-naive patients with advanced HIV infection. Abstracts of the Eighth International Congress on Drug Therapy in HIV Infection; 2006; Glasgow, UK. Abstract P9.
44. Domingo P, Suárez-Lozano I, Torres F, et al. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. J Antimicrob Chemother. 2008;61:1348–58. [PubMed] 45. Mugavero MJ, May M, Harris R, et al. Does short-term virologic failure translate to clinical events in antiretroviral-naive patients initiating antiretroviral therapy in clinical practice? AIDS. 2008;22:2481–92. [PMC free article] [PubMed] 46. Keiser P, Nassar N, White C, et al. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study. HIV Clin Trials. 2002;3:296–303. [PubMed] 47. Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis. 2008;197:1006–10. [PubMed]
48. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine/lamivudine), for the treatment of antiretroviral-naïve subjects infected with R5 HIV 1: week 48 results of the MERIT study. Abstracts of the Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007; Sydney, Australia. Abstract WESS104.
49. Saag M, Heera J, Goodrich J, et al. Reanalysis of the MERIT study with the enhanced Trofile™ assay. Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008; Washington, DC, USA. Washington, DC, USA: American Society for Microbiology; Abstract H-1232.
50. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis. 2008;198:1113–22. [PubMed]
51. Steigbigel R, Kumar P, Eron J, et al. 48-week results from BENCHMRK-2, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA, USA. Alexandria, VA, USA: Foundation for Retrovirology and Human Health; Abstract 789.
52. Cooper DA, Gatell J, Rockstroh J, et al. 48-week results from BENCHMRK-1, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA, USA. Alexandria, VA, USA: Foundation for Retrovirology and Human Health; Abstract 788.
53. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125–33. [PubMed]
54. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naïve HIV-1-infected patients: 96-week data. Abstracts of the Seventeenth International AIDS Conference; 2008; Mexico City, Mexico. Abstract TUAB0102.
55. Lennox J, DeJesus E, Lazzarin A. STARTMRK, a phase III study of the safety and efficacy of raltegravir (RAL)-based vs efavirenz (EFV)-based combination therapy in treatment-naïve HIV-infected patients. Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008; Washington, DC, USA. Washington, DC, USA: American Society for Microbiology; Abstract H-896a.
56. Zolopa AR, Lampiris H, Blick G, et al. The HIV integrase inhibitor elvitegravir (EVG/r) has potent and durable antiretroviral activity in treatment-experienced patients with active optimized background therapy (OBT). Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherpy; 2007; Chicago, IL, USA. Washington, DC, USA: American Society for Microbiology; Abstract 143LB.
57. Santoscoy M, Cahn P, Gonsalez C, et al. TMC278 (rilpivirine), an investigational next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naive patients: 96-week results of study C204. Abstracts of the Seventeenth International AIDS Conference; 2008; Mexico City, Mexico. Abstract TUAB0103.
58. US National Institutes of Health. A Clinical Trial Comparing Etravirine to Efavirenz in Combination with 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients. http://clinicaltrials.gov/ct2/show/NCT00903682. (13 August 2009, date last accessed) 59. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8:164–72. [PubMed]
60. Cassetti I, Madruga JV, Etze A, et al. The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naive patients through seven years. Abstracts of the Seventeenth International AIDS Conference; 2008; Mexico City, Mexico. Abstract TUPE0057.
61. Madruga JR, Cassetti I, Suleiman JM, et al. The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials. 2007;8:381–90. [PubMed] 62. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes—a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535–40. [PubMed] 63. Bartlett JA, Chen SS, Quinn JB. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clin Trials. 2007;8:221–6. [PubMed] 64. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272–S278. [PubMed] 65. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:e438. [PMC free article] [PubMed] 66. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8:282–92. [PubMed] 67. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3:371–8. [PubMed] 68. Moyle G. The assessing patients' preferred treatments (APPT-1) study. Int J STD AIDS. 2003;14(Suppl 1):34–6. [PubMed] 69. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310. [PubMed] 70. DeJesus E, Ruane P, McDonald C, et al. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials. 2008;9:103–14. [PubMed] 71. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2009;51:562–8. [PubMed]
72. DeJesus E, Young B, Flaherty J, et al. Simplification of antiretroviral therapy with efavirenz/emtricitabine/tenofovir DF single tablet regimen unmodified antiretroviral therapy in virologically suppressed, HIV-1 infected patients. Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008; Washington, DC, USA. Washington, DC, USA: American Society for Microbiology; Abstract H-1234.
73. Abgrall S, Yeni PG, Bouchaud O, et al. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. AIDS. 2006;20:2099–106. [PubMed] 74. Abgrall S, Yeni PG, Bouchaud O, et al. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir. Clin Infect Dis. 2007;44:120–7. [PubMed] 75. Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036–46. [PubMed] 76. Martinez E, Arnaiz JA, Podzamczer D, et al. Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. AIDS. 2007;21:367–9. [PubMed] 77. Martinez E, Gatell JM. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification. AIDS. 2007;21:1829–30. [PubMed] 78. Bannister WP, Ruiz L, Cozzi-Lepri A, et al. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS. 2008;22:367–76. [PubMed] 79. Thomson MM, Nájera R. Increasing HIV-1 genetic diversity in Europe. J Infect Dis. 2007;196:1120–4. [PubMed] 80. Soares EA, Santos AF, Sousa TM, et al. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS ONE. 2007;2:e730. [PMC free article] [PubMed] 81. Hemelaar J, Gouws E, Ghys PD, et al. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2006. AIDS. 2006;20:W13–W23. [PubMed] 82. Grossman Z, Istomin V, Averbuch D, et al. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS. 2004;18:909–15. [PubMed] 83. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1–F5. [PubMed] 85. Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29:244–53. [PubMed] 86. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005;6:187–96. [PubMed] 87. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865–73. Study 006 Team. [PubMed] 88. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials. 2002;3:279–86. [PubMed] 89. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, management. A neurobehavioral review. AIDS Rev. 2009;11:103–9. [PubMed] 90. Arendt G, de Nocker D, von Giesen HJ, et al. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007;6:147–54. [PubMed] 91. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714–21. [PubMed]
92. Hodder S, Mounzer K, DeJesus E, et al. Patient-reported outcomes after simplification to a single tablet regimen of efavrenz (EFV)/emtricitabine (FTC)/tenofovir DF (TDF). Abstracts of the Ninth International Congress on Drug Therapy on HIV infection; 2008; Glasgow, UK. Abstract P63.
93. Zaccarelli M, Soldani F, Liuzzi G, et al. CNS side effects as main risk factor for efavirenz failure and transient HIV-RNA elevation. Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, WA, USA. Alexandria, VA, USA: Foundation for Retrovirology and Human Health; Abstract 720-T.
94. Shikuma CM, Yang Y, Glesby MJ, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095) J Acquir Immune Defic Syndr. 2007;44:540–50. [PubMed] 95. Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005;19:917–25. [PubMed] 96. Perez-Molina JA, Domingo P, Martinez E, et al. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. J Antimicrob Chemother. 2008;62:234–45. [PubMed] 97. El Hadri K, Glorian M, Monsempes C, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem. 2004;279:15130–41. [PubMed]
98. Diaz-Delfin J, Gallego-Escuredo JM, Milanski M, et al. Comparison of the effects of nevirapine with respect to efavirenz on differentiating and mature human adipocytes in culture. Abstracts of the Tenth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2008; London, UK. Abstract P-01.
99. Fisher M, Moyle G, Ebrahimi R, et al. Switching from Combivir (CBV, AZT/3TC) to Truvada (TVD, TDF/FTC) maintains viral suppression, prevents and reverses limb fat loss, and improves biochemical parameters: results of a 48 week randomised study. Abstracts of the Eleventh European AIDS Conference; 2007; Abstract PS5/7.
100. Dube MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. J Acquir Immune Defic Syndr. 2007;45:508–14. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. [PubMed] 101. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42:273–80. [PubMed] 102. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23:1109–18. [PMC free article] [PubMed] 103. Estrada V, De Villar NG, Larrad MT, et al. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis. 2002;35:69–76. [PubMed] 104. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995;1:417–22. [PubMed] 105. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and the mitochondria. Biochim Biophys Acta. 2006;1757:700–7. [PubMed] 106. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003. [PubMed] 107. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35. [PubMed] 109. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22:2155–63. [PubMed]
111. Pozniak AL, Gallant JE, Staszewski S, et al. Similar 96-week efficacy profile regardless of baseline charcteristic variable for tenofovir disoproxil fumarate (TDF) versus stavudine (D4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients. Abstracts of the IAS Conference on HIV Pathogenesis and Treatment; 2003; Paris, France. Abstract 559.
113. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis. 2003;23:173–82. [PubMed] 114. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182–9. [PubMed] 115. Brück S, Witte S, Brust J, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res. 2008;13:343–8. [PubMed] 116. Ena J, Amador C, Benito C, et al. Risk and determinants of developing severe liver toxicity during therapy with nevirapine- and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS. 2003;14:776–81. [PubMed] 117. Katsounas A, Frank A, Klinker H, et al. Efavirenz-therapy in HIV-patients with underlying liver disease: importance of continuous TDM of EFV. Eur J Med Res. 2007;12:331–6. [PubMed] 118. Pereira SA, Caixas U, Branco T, et al. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. Br J Clin Pharmacol. 2008;66:551–5. [PubMed] 119. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS. 2004;18:767–74. [PubMed] 120. Berenguer J, Bellon JM, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2008;46:137–43. [PubMed] 121. Margot NA, Lu B, Cheng A, et al. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med. 2006;7:442–50. [PubMed] 122. Breen RA, Swaden L, Ballinger J, et al. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs. 2006;66:2299–308. [PubMed] 123. Matteelli A, Regazzi M, Villani P, et al. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res. 2007;5:349–53. [PubMed]
124. Hollender E, Stambaugh J, Ashkin D, et al. The concomitant use of rifabutin and efavirenz in HIV/TB co-infected patients. Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections; 2003; Boston, MA, USA. Alexandria, VA, USA: Foundation for Retrovirology and Human Health; Abstract 785.
125. German P, Greenhouse B, Coates C, et al. Drug interaction between antimalarial drugs and efavirenz. Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, CA, USA. Alexandria, VA, USA: Foundation for Retrovirology and Human Health; Abstract 577.
126. Bruce RD, McCance-Katz E, Kharasch ED, et al. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis. 2006;43(Suppl 4):S216–S223. [PubMed] 127. McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis. 2005;41(Suppl 1):S89–S95. [PubMed] 128. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005;39:307–12. [PubMed] 129. Fellay J, Marzolini C, Decosterd L, et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol. 2005;60:865–73. [PubMed]
130. Joshi AS, Fiske WD, Benedek IH, et al. Lack of a pharmacokinetic interaction between efavirenz and ethinyl estradiol in healthy female volunteers. Abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; 1998; Chicago, IL, USA. Alexandria, VA, USA: Foundation for Retrovirology and Human Health; Abstract 348.
131. Poirier JM, Guiard-Schmid JB, Meynard JL, et al. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors. AIDS. 2006;20:1087–9. [PubMed]
132. Klein CE, Cai Y, Chiu YL, et al. Pharmacokinetics of lopinavir and ritonavir after multiple dose administration of lopinavir/ritonavir tablet coadministered with efavirenz. Eighth International Conference on Drug Therapy of HIV Infection; 2006; Glasgow, UK. Poster #366.
133. Faroux S, Berhoune M, Sauvageon-Martre H, et al. Therapeutic drug monitoring of efavirenz in HIV-infected patients treated by Sustiva associated or not with ritonavir. Abstracts of the Fourth International Workshop on Clinical Pharmacology of HIV Therapy; 2003; Cannes, France. Abstract 5.12.
134. Kwara A, Lartey M, Sagoe KW, et al. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol. 2008;48:1032–40. [PMC free article] [PubMed] 135. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;61:914–8. [PMC free article] [PubMed] 136. Llibre JM, Santos JR, Puig T, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother. 2008;62:909–13. [PubMed] 137. Lapadula G, Calabresi A, Castelnuovo F, et al. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther. 2008;13:601–5. [PubMed]
138. Vingerhoets J, Peeters M, Azjin H, et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine (ETR): multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data. Abstracts of the Seventeenth International HIV Drug Resistance Workshop; 2008; Sitges, Spain. Abstract 24.
139. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39–48. [PubMed] 140. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38. [PubMed] 141. Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med. 2008;9:883–96. [PubMed] 142. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4:65–72. [PubMed] 143. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53:696–9. [PubMed]
144. Gross R, Yip B, Wood E, et al. Boosted PI are more forgiving of suboptimal adherence than non-boosted PI or NNRTI. Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections; 2006; Denver, CO, USA. Alexandria, VA, USA: Foundation for Retrovirology and Human Health; Abstract 533.
145. Bangsberg D, Hahn J, Weiser S, et al. Less than 95% adherence to ritonavir-boosted protease inhibitors leads to viral suppression: an update to address currently prescribed antiretroviral regimens. Abstracts of the Fourth IAS Conference; 2007; Sydney, Australia. Abstract WEPEB111.
146. Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr. 2008;49:266–71. [PMC free article] [PubMed] 147. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223–31. [PubMed] 148. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158–63. [PubMed] 149. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE. 2008;3:e2783. [PMC free article] [PubMed] 150. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36:808–16. [PubMed]
151. Maggiolo F, Airoldi M, Trotta MP, et al. Effect of a fixed-dose combination of emtricitabine, tenofovir and efavirenz on adherence and treatment acceptability (ADONE study). Ninth International Conference on Drug Therapy in HIV Infection; 2008; Poster 167.
152. van Leth F, Conway B, Laplume H, et al. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz. Antivir Ther. 2004;9:721–8. [PubMed] 153. Bucciardini R, Fragola V, Massella M, et al. Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy. AIDS Res Hum Retroviruses. 2007;23:1215–22. [PubMed] 154. Santos J, Palacios R, López M, et al. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naive patients: the VESD study. HIV Clin Trials. 2005;6:320–8. [PubMed] 155. Schackman BR, Ribaudo HJ, Krambrink A, et al. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007;46:547–54. [PubMed] 156. Asch SM, Kilbourne AM, Gifford AL, et al. Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med. 2003;18:450–60. [PMC free article] [PubMed] 157. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005;38:560–5. [PubMed] 158. Basu RP, Grimes RM, Helmy AF. Cost to achieve an undetectable viral load using recommended antiretroviral regimens. HIV Clin Trials. 2006;7:309–18. [PubMed] 159. Beck EJ, Mandalia S, Youle M, et al. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996–2002) Int J STD AIDS. 2008;19:297–304. [PubMed]